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Abstract
 
Antibody-secreting plasma cells are nonrecirculatory and lodge in splenic red pulp, lymph node
medullary cords, and bone marrow. The factors that regulate plasma cell localization are poorly
defined. Here we demonstrate that, compared with their B cell precursors, plasma cells exhibit
increased chemotactic sensitivity to the CXCR4 ligand CXCL12. At the same time, they
downregulate CXCR5 and CCR7 and have reduced responsiveness to the B and T zone
chemokines CXCL13, CCL19, and CCL21. We demonstrate that CXCL12 is expressed
within splenic red pulp and lymph node medullary cords as well as in bone marrow. In chi-
meric mice reconstituted with CXCR4-deficient fetal liver cells, plasma cells are mislocalized
in the spleen, found in elevated numbers in blood, and fail to accumulate normally in the bone
marrow. Our findings indicate that as B cells differentiate into plasma cells they undergo a co-
ordinated change in chemokine responsiveness that regulates their movements in secondary
lymphoid organs and promotes lodgment within the bone marrow.
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Introduction
 
Plasma cells play a critical role in humoral immunity by
functioning as factories for antibody production. In the case
of T cell–dependent antibody responses, antigen-engaged B
cells receive T cell help in the region of the T zone–bor-
dering follicles. A focus of differentiating B cell blasts soon
appears and the cells move over the next day or two out of
the lymphoid T zones. In the spleen, the cells move
through marginal zone “bridging channels” and many of
the cells lodge in foci near vessels or collagenous fibers in
the red pulp (1–3). In lymph nodes, plasma cells are found
distributed between the lymphatic sinuses of the medullary
cords (4, 5). Later in the response, plasma cells begin ap-
pearing in the bone marrow (6–9). While the plasma cell
response is ongoing, small numbers of B cells colonize B
cell follicles and differentiate into germinal center cells. Af-
ter several days of development, germinal centers begin
giving rise to memory B cells and more plasma cells (10,
11). Plasma cells emanating from germinal centers are
thought to preferentially home to the bone marrow (4, 12,
13). A similar series of events takes place in secondary im-
mune responses except with faster kinetics and substantially
greater accumulation of plasma cells in the bone marrow (6,
8). Most of the plasma cells that lodge in splenic red pulp
and lymph node medullary cords live for only a few days
(8, 14), whereas plasma cells that home to the bone marrow
include cells that live for weeks or months (15, 16).
Despite the well-characterized series of migration events,
relatively little has been known about the cues directing
plasma cell movements. Recent studies have highlighted
the importance of members of the chemokine family in
guiding cell movements within primary and secondary
 
lymphoid organs (17). Chemokines form a family of 
 
 
 
40
members and most are secreted proteins. All can act as
chemoattractants and many have additional functions (17).
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Chemokine receptors are all members of the seven-trans-
membrane family of heterotrimeric G-protein–coupled re-
ceptors. Progenitor, immature, and mature B cells express
the chemokine receptor CXCR4, and its ligand, CXCL12
(previously called stromal cell–derived factor [SDF]
 
*
 
-1), is
highly expressed by bone marrow stromal cells (18, 19).
Genetic studies have established that CXCL12 and CXCR4
are needed for retention of developing B cells in the
bone marrow (20, 21). As they mature to an IgD
 
 
 
 stage,
B cells upregulate CXCR5 and acquire responsiveness
to CXCL13 (BLC), a chemokine made in follicles of
secondary lymphoid organs (22). Mature B cells also ex-
press CCR7, a receptor for the T zone chemokines CCL19
(ELC) and CCL21 (SLC), and they are able to migrate to
these chemokines (17). Pointing toward the possibility that
changes in chemokine responsiveness are important in di-
recting plasma cell movements, an analysis of mouse and
human plasmacytomas showed that, compared with naive
B cells, they had downregulated CXCR5 (23, 24).
Previous studies have demonstrated that CXCL12 is
made at high levels in bone marrow, a site of plasma cell
homing. We demonstrate here that CXCL12 is also made
in splenic red pulp and lymph node medullary cords.
Plasma cells are shown to downregulate CXCR5 and
CCR7 and have reduced responsiveness to B and T zone
chemokines CXCL13, CCL19, and CCL21. By contrast,
we find that plasma cells express CXCR4 and have in-
creased sensitivity to CXCL12. Using CXCR4-deficient
fetal liver chimeras, we show that CXCR4 plays an impor-
tant role in regulating plasma cell positioning in spleen and
plasma cell lodgment in bone marrow.
 
Materials and Methods
 
Mice and Chimeras.
 
C57BL/6 (B6), B6-Igh
 
a
 
 Thy1
 
a
 
 GPi1
 
a
 
,
and 129 mice were purchased from the Jackson ImmunoRe-
search Laboratories and B6-CD45.1 mice from Charles River
Laboratories. CXCR4
 
 
 
/
 
 
 
 mice (25) were on a 129
 
   
 
B6 mixed
genetic background. CXCR4
 
 
 
/
 
 
 
 mice were intercrossed, em-
bryos harvested on days 15–17, and livers isolated as described
previously (26). To screen for CXCR4 genotype, 5% of the fetal
liver cells were used as a source of DNA in PCR with primers:
CXCR4-1 (5
 
 
 
-gatcctggtcatgggttacc-3
 
 
 
) and CXCR4-2 (5
 
 
 
-tgat-
gcagtaacaggagagg-3
 
 
 
) to detect the wild-type allele; and
CXCR4-1 together with a neomycin gene specific primer (5
 
 
 
-
cttgacgagttcttctgagggga-3
 
 
 
) to detect the targeted allele. For 100%
chimeras, CXCR4
 
 
 
/
 
 
 
, 
 
 
 
/
 
 
 
 or, 
 
 
 
/
 
 
 
 
 
fetal liver cells were used to
reconstitute 6–10-wk-old B6 or B6-CD45.1 mice that had been
lethally irradiated by exposure to two 550 rad doses, separated by
3 h of 
 
 
 
 irradiation from a Cesium source. During reconstitution,
mice were maintained on water containing antibiotics as de-
scribed previously (27). Sex-matched chimeras were used for
immunizations after 5–6 wk of reconstitution. Wild-type/mutant-
mixed chimeras were made using lethally irradiated 129 recipi-
ents and injecting 1–2
 
   
 
10
 
6
 
 cells that were a mix of CXCR4-
deficient IgH
 
b
 
 fetal liver (90–95%) and CXCR4
 
 
 
/
 
 
 
 B6 IgH
 
a
 
bone marrow (5–10%). To make matching wild-type/wild-type
control chimeras it was necessary to use lower amounts of
CXCR4
 
 
 
/
 
 
 
 IgH
 
b
 
 fetal liver (10%) in the mixture to ensure that
the frequency of IgH
 
b
 
 cells in the periphery was similar to the fre-
quency of CXCR4
 
 
 
/
 
 
 
 cells in the wild-type/mutant chimeras.
Flow cytometric analysis of spleen cells from reconstituted ani-
mals using allele-specific reagents showed 5–50% of total B cells
were CXCR4
 
 
 
/
 
 
 
 or CXCR4
 
 
 
/
 
  
 
fetal liver–derived and 50–95%
were derived from the wild-type bone marrow.
 
Immunizations.
 
B6 mice were immunized with 100 
 
 
 
g of
alum-precipitated nitro-phenyl (NP) chicken 
 
 
 
-globulin (CGG;
Solid State Sciences) intraperitoneally in a volume of 200 
 
 
 
l. In
some experiments, mice received a secondary immunization of
the same type 3–5 wk later. For T cell–independent responses,
mice received 15–20 
 
 
 
g of NP-Ficoll (Solid State Sciences) in
100 
 
 
 
l of PBS. Spleen, lymph nodes, blood, and bone marrow
were harvested from mice at the indicated time points as de-
scribed previously (27).
 
Chemokines and Chemotaxis Assays.
 
HIS
 
6
 
-tagged murine CXCL13/
BLC was prepared as described previously (28). The HIS
 
6
 
-
tagged murine CCL21 construct was provided by M. Gunn
(Duke University, Durham, NC). The construct was transformed
into 
 
Escherichia coli
 
 TAP302 cells and HIS
 
6
 
-tagged CCL21 was
purified by the same protocol used for HIS
 
6
 
-tagged CCL19 (29).
Commercial mouse CCL21 (R&D Systems) was used in some
experiments with similar results. Synthetic CXCL12 was from
Gryphon Laboratories. Chemotaxis assays were performed as de-
scribed previously (29) with the exception that splenocytes were
incubated in 10% FCS and 5% CO
 
2
 
 at 37
 
 
 
C for 30 min before
RBC lysis.
 
Generation of CCL19–Fc Fusion Protein.
 
CCL19–Fc was con-
structed by first using a PCR-based insertion to add a Kozak se-
quence and a 3
 
 
 
 splice recognition site to the full-length CCL19
cDNA (29). The fragment was cut with HindIII and SacI (NEB)
and inserted into the C
 
 
 
1 vector (provided by Peter Lane, Uni-
versity of Birmingham, Birmingham, UK; reference 30). This
construct was electroporated into the J558L plasmacytoma cell
line and stable clones were selected using GPT selective media
(31). Culture supernatants were tested for activity by their ability
to induce a calcium flux in fluo-3–loaded spleen cells as described
previously (32). Culture supernatant from a positive clone was
purified over a protein A column and eluted using 0.1 M
sodium citrate (Amersham Pharmacia Biotech), pH 4.0, and
0.2 M NaCl. On SDS-PAGE the purified CCL19–Fc protein
ran at the expected size of 
 
 
 
40 kD and in Western blotting it
was reactive with goat anti–human Fc (Jackson ImmunoRe-
search Laboratories) and goat anti-CCL19 (R&D Systems). Cell
lines transfected with murine CCR7 (29), but not vector-control
transfected cells, were stained by the CCL19–Fc fusion protein in
flow cytometric analysis.
 
Flow Cytometry.
 
First, cells were incubated with rat anti-
CD16/CD32 (BD PharMingen) to block Fc receptors. CCL19–
Fc, CXCL12–Fc (33), hLFA3–Fc (provided by Jeff Browning,
Biogen, Inc., Cambridge, MA), or rabbit anti-CXCR5 (34) was
then added, followed by PE-conjugated anti–human Fc
 
 
 
 (Jackson
ImmunoResearch Laboratories) or goat anti–rabbit Ig (BD
PharMingen) preincubated for 30–60 min with 2% normal rat and
normal mouse serum (Sigma-Aldrich). Rat anti-B220–FITC, rat
anti–syndecan-1 (CD138) –PE, and streptavidin cychrome (BD
PharMingen) were added to the cells stained with chemokine re-
ceptor reagents. For CCL19–Fc and CXCL12–Fc specificity con-
trols, soluble chemokine (5 
 
 
 
g/ml) was added at the initial step
together with the Fc-receptor blocking antibody. For staining af-
 
*
 
Abbreviations used in this paper:
 
 AP, alkaline phosphatase; CGG, chicken
 
 
 
-globulin; HRP, horseradish peroxidase; NP, nitro-phenyl; SDF, stro-
mal cell–derived factor. 
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ter chemotaxis assays, B220–FITC and syndecan-PE were used.
Stained cells were analyzed on a FACScan™ (Becton Dickinson).
 
Histology and In Situ Hybridization.
 
Spleens and lymph nodes
of unimmunized and immunized B6 mice were frozen in Tissue-
Tek OCT compound (Baxter Scientific) and cryostat sections (7–8
 
 
 
m) were fixed in acetone and stained as described previously
(28) with the following reagents: goat anti-CXCL12 (Santa Cruz
Biotechnology, Inc.); rat anti–syndecan–PE (BD PharMingen),
or rat anti–IgM-biotin (Caltag). For some experiments, the anti-
CXCL12 signal was amplified using a biotinylated donkey anti–
goat antibody (Jackson ImmunoResearch Laboratories). Rat
antibodies were detected using alkaline phosphatase (AP)–conju-
gated donkey anti–rat IgG or horseradish peroxidase (HRP)–
conjugated donkey anti–rat IgG (Jackson ImmunoResearch Lab-
oratories). Biotinylated reagents were detected using the
SA-ABC AP or SA-ABC HRP kit (Vector Laboratories) or SA-
AP (Jackson ImmunoResearch Laboratories). Goat antibodies were
detected using AP-conjugated swine anti–goat IgG (Caltag). AP
and HRP were detected as described previously (28) with the ad-
ditional use of Fast Blue (Sigma-Aldrich). In situ hybridization
was performed as described previously (29) using nucleotides
 
 
 
11 to 
 
 
 
1,064 of SDF-1
 
 
 
 (35) as a template for making digoxi-
genin-labeled riboprobes.
 
ELISPOT Assays.
 
Freshly isolated spleen, blood, bone mar-
row, and lymph node cells were used in ELISPOT assays as de-
scribed previously (36). Plates were precoated with NP
 
25
 
-BSA
(Solid State Sciences). IgM was detected with anti–mouse IgM
biotin (Caltag) and IgG with anti–mouse IgG biotin (Jackson Im-
munoResearch Laboratories) followed by SA-AP. IgM
 
a
 
, IgM
 
b
 
,
IgG1
 
a
 
, and IgG1
 
b
 
 were detected using biotyinylated allele-specific
antibodies (BD PharMingen).
 
Results
 
CXCL12 Expression in Spleen and Lymph Nodes.
 
Northern blot analysis established that there is constitutive
CXCL12 expression within primary and secondary lym-
phoid tissues (37, 38). Using in situ hybridization we found
that CXCL12 mRNA was expressed in the splenic red
pulp and in marginal zone bridging channels of white pulp
cords (Fig. 1, A and C). Within lymph nodes, CXCL12
Figure 1. Expression pattern of CXCL12
(SDF-1) in spleen and lymph node and co-
distribution of CXCL12-expressing cells
and plasma cells. In situ hybridization analy-
sis of CXCL12 in spleen (A and C) and
lymph node (B and E) in combination with
peanut agglutinin to detect germinal centers
(A and B) or B220 to localize B cell areas (C
and E). D and F are from sections nearby in
the tissue to those in C and E, respectively,
and are stained to detect B cells (IgD, blue)
and plasma cells (syndecan, brown). Insets in
A and B show detail of in situ hybridization
signal. Arrows in C and D point to locations
where CXCL12 and syndecan staining
colocalize. F, follicle; GC, germinal center;
MC, medullary cords; RP, red pulp; T, T
zone. (A–F) Original magnifications: 5 .
(Insets) Original magnifications: 20 . 
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was expressed throughout the medullary cords (Fig. 1 B).
Little or no hybridization was detected within follicles or T
cell areas in spleen and lymph nodes. However, in several
cases where large germinal centers were present, CXCL12
expression was detected in areas that reached close proxim-
ity with the germinal center (Fig. 1 B). As splenic red pulp
and lymph node medullary cords are sites of plasma cell lo-
calization, we examined whether plasma cells localized in
areas of CXCL12 expression. Comparison of CXCL12-
hybridized and B220-stained spleen sections with nearby sec-
tions that were stained for the plasma cell marker, synde-
can-1, revealed that plasma cell clusters were in areas that
overlapped with regions of CXCL12 expression (Fig. 1, C
and D). Similar observations were made in lymph nodes
(Fig. 1, E and F). Northern blot analysis of spleen RNA
from B cell–deficient mice showed CXCL12 expression
was maintained at wild-type levels (data not shown), indi-
cating that B-lineage cells do not make a substantial contri-
bution to constitutive CXCL12 production. As most stud-
ies have indicated that CXCL12 is a SDF (18, 35, 39–41),
we suggest that stromal cells in splenic red pulp and lymph
node medullary cords are the predominant source of
CXCL12 in these tissues.
 
Plasma Cells Have Altered Chemokine Responsiveness.
 
The overlapping distribution of plasma cells and areas of
CXCL12 expression led us to examine whether plasma
cells could chemotax to CXCL12. Transwell chemotaxis
assays were performed with spleen cells isolated from mice
at day six after intraperitoneal immunization with NP-
CGG in alum, near the peak of the plasma cell response.
Consistent with previous findings (18, 42), CXCL12 was
an efficacious attractant of mature (B220
 
 
 
 syndecan
 
 
 
) B
cells, with a maximum response occurring at 
 
 
 
30 nM
CXCL12 (Fig. 2, A and B). Syndecan-1
 
 
 
 plasma cells also
showed a chemotactic response towards CXCL12 and, no-
tably, they exhibited greater dose sensitivity than mature B
cells, responding maximally to 
 
 
 
10 nM CXCL12 (Fig. 2,
A and C). Similar findings were made with plasma cells
generated in vitro by incubating cells for 4 d with LPS (data
not shown). Presently it is unclear whether the lower over-
all magnitude of the plasma cell response to CXCL12 com-
pared with naive B cells is due to heterogeneity in the
plasma cell population or a lower ability of the in vitro as-
say to support plasma cell migration. By contrast with their
ability to respond to CXCL12, plasma cells had mark-
edly reduced responsiveness to the B zone chemokine,
CXCL13/BLC (Fig. 2 C), and the T zone chemokines,
CCL21/SLC (Fig. 2 C) and CCL19/ELC (data not
shown), across a broad range of concentrations.
 
Altered Chemokine Receptor Expression on Plasma Cells.
 
To determine whether the altered chemokine responsive-
ness of plasma cells reflected changes in chemokine recep-
tor expression, cells were stained with CXCL12–Fc or
CCL19–Fc, or with antibodies against CXCR5 (Fig. 3).
Compared with naive B cells, plasma cells consistently ex-
hibited elevated CXCL12–Fc staining (Fig. 3 A). Similar
observations were made with plasma cells from lymph
nodes and bone marrow (data not shown). Incubation of
 
the cells with a molar excess of CXCL12, but not CCL19,
reduced the CXCL12–Fc staining of plasma cells, confirm-
ing that the binding was chemokine specific (Fig. 3 B). To
test the specificity for CXCR4, spleen cells were obtained
from mice that had been irradiated and reconstituted with
fetal liver cells from CXCR4
 
 
 
/
 
 
 
 or CXCR4
 
 
 
/
 
 
 
 embryos
(25). CXCL12–Fc staining of CXCR4
 
 
 
/
 
 
 
 B cells (Fig. 3
C) and plasma cells (Fig. 3 D) was reduced compared with
the heterozygote controls, establishing that both cell types
express CXCR4. However, CXCR4-deficient cells con-
tinued to show detectable staining with CXCL12–Fc, indi-
Figure 2. Chemotactic response profiles of B cells and plasma cells to
CXCL12, CXCL13 (BLC), and CCL21 (SLC). (A) Flow cytometric
analysis of input cells and cells that migrated to the lower well of a trans-
well chamber in the absence of chemokine (no chemokine) or in re-
sponse to 1  g/ml CXCL13 or 0.1  g/ml CXCL12. (B and C) Sum-
mary of chemotaxis data in response to the indicated concentrations of
chemokine, expressed as the percentage of transmigrated input cells. B
cells and plasma cells were identified using gates G1 and G2 shown in A.
Bars represent means of duplicate transwells. Assays were performed with
spleen cells from mice 6 d after primary NP-CGG/alum immunization.
Data are from one experiment that is representative of more than four ex-
periments for each chemokine. 
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cating that CXCL12 binds to surface molecules in addition
to CXCR4. Previous work has shown that CXCL12 binds
strongly to heparan sulfate (43) and, it is therefore possible
that some of the CXCL12–Fc staining of plasma cells is due
to binding to heparan sulfate-containing proteoglycans,
such as syndecan-1 (44). Nevertheless, CXCR4-deficient
B cells and plasma cells were unable to respond to
CXCL12 in chemotaxis assays (data not shown), indicating
that CXCR4 is the only functional chemotactic receptor
for CXCL12 on these cells.
By contrast with CXCR4, plasma cell expression of
CXCR5 was substantially reduced (Fig. 3 E). To measure
expression levels of CCL19 and CCL21 receptors, we gen-
erated a CCL19–Fc fusion protein (see Materials and
Methods). CCL19–Fc staining was markedly reduced on
plasma cells as compared with B cells (Fig. 3 F). The stain-
ing of B cells could be blocked by the addition of CCL19
and partially blocked with the addition of CCL21, but was
not blocked at all by a variety of other chemokines (Fig. 3
G, and data not shown), establishing that the staining was
specific and most likely a result of binding to CCR7. In
summary, plasma cells appear to have decreased expression
of CXCR5 and CCR7 and increased expression of
CXCL12-binding molecules. These changes are consistent
with the altered chemokine response profile of plasma cells
compared with naive B cells shown in Fig. 2.
 
Altered Plasma Cell Localization in Spleen of CXCR4
 
 
 
/
 
 
 
 
 
Fetal
Liver Chimeras.
 
To test whether CXCR4 and CXCL12
play a role in plasma cell migration or lodgment, lethally
irradiated mice that had been reconstituted with
CXCR4-deficient fetal liver cells were immunized with
NP-CGG, a T cell–dependent antigen. Intraperitoneal in-
jections were performed to favor plasma cell responses
within the spleen. Staining for a congenic marker, CD45.1,
to distinguish donor and recipient cells established that
 
 
 
90% of B220
 
 
 
 B cells (97
 
   
 
2%, 
 
n 
 
  
 
7) and syndecan-1
 
 
 
plasma cells (95
 
   
 
3%, 
 
n 
 
  7) in CXCR4 /  fetal liver chi-
meras were of donor origin. Splenic B cell numbers in
CXCR4-deficient chimeras were within threefold of con-
trols, despite marked reductions in bone marrow pre-B and
immature B cell numbers, as observed previously (20, 21).
Enumeration of anti-NP antibody-secreting cell frequencies
in the spleen at day 4 after immunization revealed efficient
induction of NP-specific IgM-secreting plasma cells in
CXCR4 /  fetal liver chimeric mice (Fig. 4 A). Numbers
of IgM-secreting cells remained within twofold of wild-type
at day 6, while numbers of CXCR4-deficient IgG-secreting
cells were significantly lower than in controls (Fig. 4 B).
Figure 3. Increased CXCL12 binding and de-
creased CXCR5 expression and CCL19 (ELC)
binding by plasma cells compared with B cells.
Spleen cells from mice immunized with NP-CGG/
alum 6 d before were stained with B220, syndecan,
and CXCL12-Fc (A–D), anti-CXCR5 (E), or
CCL19–Fc (F and G), and analyzed by flow cy-
tometry. B cells and plasma cells were identified as
in the legend to Fig. 2 A. Controls in A, B, D, and
F are plasma cells and in C and G are B cells,
stained with LFA-3–Fc (A–D, F and G), or no pri-
mary antibody (E). In B and F, cells were preincu-
bated with the indicated chemokine before addi-
tion of the Fc fusion protein. In C and D, cells
were from irradiated mice that had been reconsti-
tuted for 6 wk with CXCR4 /  or CXCR4 / 
fetal liver cells before immunization. In all other
panels, cells were from immunized wild-type mice.
Figure 4. Antigen-specific IgM and IgG antibody-secreting cell num-
bers in spleen after primary immunization of CXCR4 /  and control
(CXCR4 /  or CXCR4 / ) fetal liver chimeras. Chimeric mice were
immunized intraperitoneally with NP-CGG in alum and 4 or 6 d later,
spleen cells were isolated and antibody-secreting cell frequencies mea-
sured by anti–NP-ELISPOT assay. Bars represent mean number of
ELISPOTs per spleen and error bars indicate 95% confidence intervals for
data from groups of four mice at days 4 and 8 mice at day 6. No differ-
ences were observed between responses in  /  and  /  animals. Aver-
age number of splenocytes per mouse: day 4, 9.4   107  / , 4.3   107
 / ; day 6, 1.1   108  /  and  / , 7.0   107  / .50 CXCR4 Regulates Plasma Cell Distribution
Examination of the plasma cell distribution within the
spleen revealed a marked disturbance in CXCR4 /  fe-
tal liver chimeras. Although CXCR4 /  and wild-type
plasma cells appeared to exit white pulp areas with similar
efficiency, CXCR4 /  cells did not lodge with normal ef-
ficiency in clusters near vessels or vessel-associated fibers in
the red pulp (Fig. 5). Instead, the CXCR4-deficient plasma
cells were more dispersed within the red pulp or were
found associated with the marginal zone (Fig. 5, A–D). In-
terestingly, in addition to the altered plasma cell distribu-
tion, the frequency of B220  B cells within the red pulp of
CXCR4 /  fetal liver chimeras appeared greatly reduced
compared with the controls (Fig. 5, A–D). Antibody re-
sponses to NP are dominated by cells expressing the   light
chain (45). As with the larger population of plasma cells
detected with anti-IgG and syndecan-specific reagents,
 -positive plasma cells in CXCR4 /  chimeras were fre-
quently found in the marginal zone area instead of localiz-
ing in the red pulp (Fig. 5, E and F). Plasma cells induced
in response to the T cell–independent antigen, NP-Ficoll,
also showed an aberrant distribution within spleen (Fig. 5,
G and H). Therefore, CXCR4 is required for normal
plasma cell localization in vessel- and fiber-associated clus-
ters within the splenic red pulp.
CXCR4 Is Required for Plasma Cell Accumulation in Bone
Marrow. While peripheral lymphoid tissues are important
sites for lodgment of short-lived plasma cells, the bone
marrow is the principal site of accumulation of long-lived
Figure 5. Altered plasma cell distribution in
spleens of CXCR4 /  fetal liver chimeras. Spleen
sections from CXCR4 /  or CXCR4 /  fetal
liver chimeric mice immunized 6 d earlier with
NP-CGG in alum (A–F) or with NP-Ficoll (G and
H) were stained with the indicated antibodies (la-
bels are the same color as the reaction product for
that marker). Note that plasma cells contain large
amounts of cytoplasmic antibody and stain strongly
with the antibody-specific reagents (IgG,  , or
IgM, all in blue).51 Hargreaves et al.
plasma cells. Generation of long-lived plasma cells and re-
distribution of plasma cells from peripheral lymphoid tis-
sue to bone marrow occurs to a substantially greater extent
in secondary compared with primary responses (6, 8).
Therefore, to test whether CXCR4 functions in plasma cell
trafficking to bone marrow, NP-CGG primed CXCR4 / 
fetal liver chimeras and control chimeras were given sec-
ondary immunizations of NP-CGG, and plasma cell fre-
quencies were measured 7 d later, at the peak of the bone
marrow response (8). ELISPOT analysis showed that the
number of NP-specific IgG-secreting plasma cells in the
bone marrow was reduced more than threefold in
CXCR4 /  chimeras compared with wild-type controls
(Fig. 6 A).
Previous studies of plasma cell generation during second-
ary immune responses in wild-type mice have indicated
that many of the cells that give rise to bone marrow plasma
cells leave the spleen by days 3–4 after immunization (4,
12, 13). Enumeration of antibody-secreting cell frequencies
in spleens of mutant and wild-type chimeras at day 3 re-
vealed similar numbers, indicating that early events in-
volved in plasma cell production in the spleen during the
secondary immune response were intact (Fig. 6 B). There-
fore, we asked whether the decreased number of plasma
cells appearing in the bone marrow at day 7 could reflect a
defect in cell emigration from the blood. At day 3 of the
secondary response, high numbers ( 2,000 per milliliter)
of NP-specific IgG antibody-secreting cells were detected
in the blood of wild-type animals (Fig. 6 C), consistent
with this being an important period of plasma cell redistri-
bution from spleen to bone marrow (4, 12, 13). Compari-
son of CXCR4 /  and wild-type fetal liver chimeras at this
time point showed significantly higher numbers of anti-
body-secreting cells in the blood of CXCR4 /  chimeras
(Fig. 6 C). By day 7, the number of cells in blood had de-
creased in both wild-type and mutant animals, but numbers
in the blood of CXCR4 /  chimeras remained signifi-
cantly higher than in controls (Fig. 6 D). Flow cytometric
analysis with antibodies to syndecan confirmed that plasma
cell frequencies were elevated in the blood of CXCR4 / 
fetal liver chimeras (data not shown). These findings are
consistent with a requirement for CXCR4 for IgG anti-
body-secreting cells to migrate from blood to bone marrow
or to be retained within the marrow.
An analysis of IgM-secreting cells at day 6 of the primary
NP-CGG response revealed a similar defect in CXCR4 / 
chimeras compared with controls (Fig. 6, E and F). Al-
though the total number of antibody-secreting cells was
lower than in the secondary response, CXCR4 /  chime-
ras again had elevated numbers in the blood (Fig. 6 E) and
fewer in the bone marrow (Fig. 6 F), despite having similar
numbers in spleen (Fig. 4 B). Similar findings were made in
animals that had been given subcutaneous immunizations
with NP-CGG in complete Freund’s adjuvant to provoke
T cell–dependent immune responses in lymph nodes, and
in the response to the T cell–independent antigen, NP-
Ficoll (data not shown). Analysis at day 14 of the NP-CGG/
alum response showed an even more exaggerated differ-
ence in the number of IgM antibody-secreting cells in the
bone marrow (Fig. 6 G). Again, numbers of anti-NP anti-
body-secreting cells in the spleen of mutants and controls
were similar (Fig. 6 H). The frequency of plasma cells in
the blood at this time was too low to measure.
Intrinsic Requirement of CXCR4 for Plasma Cell Accumula-
tion in Bone Marrow. To examine whether the increased
number of antibody-secreting cells in the blood and de-
creased number in the bone marrow was due to an intrinsic
defect in plasma cells or their precursors, or due to a defect
in some other cell type, mixed bone marrow and fetal liver
chimeras were generated. Lethally irradiated 129 (IgHa)
strain mice were reconstituted with a mixture of IgHa con-
genic C57BL/6 bone marrow and CXCR4 /  (IgHb) or
CXCR4 /  (IgHb) fetal liver (Fig. 7 A). The mixing ratios
were chosen to ensure that despite the low numbers of im-
mature cells generated in the bone marrow, CXCR4 /  B
cells made a significant contribution to the B cell compart-
ment (see Materials and Methods). In several preliminary
experiments we found that bone marrow from 129 (IgHa)
Figure 6. Reduced numbers of plasma cells in bone
marrow and increased numbers in the blood of
CXCR4 /  chimeras. (A–D) NP-specific IgG anti-
body-secreting cell frequencies in CXCR4 /  or con-
trol (CXCR4 / ) chimeras after secondary immuniza-
tion with NP-CGG in alum. (E–H) NP-specific IgM
antibody-secreting cell frequencies in CXCR4 /  or
control (CXCR4 /  or CXCR4 / ) chimeras after
primary immunization with NP-CGG in alum. Tissues
were isolated at the indicated time points after immu-
nization and antibody-secreting cell frequencies deter-
mined by ELISPOT. IgM or IgG antibody-secreting
cell frequencies per organ or per milliliter of blood
were determined by NP-ELISPOT for four mice per
group at days 3 and 7 of the secondary response, and
four to seven mice per group at days 6 and 14 of the
primary response. Average number of splenocytes per
mouse: secondary day 3, 1.6   108     and 1.3   108
 / ; primary day 14, 8.9   107     and 4.3   107
 / . Bone marrow cell numbers for each group dif-
fered by  30%.52 CXCR4 Regulates Plasma Cell Distribution
mice efficiently outcompeted C57BL/6 cells during recon-
stitution (data not shown). Therefore, we used bone mar-
row from an IgHa congenic C57BL/6 strain as the wild-
type partner. An analysis of mixed CXCR4 /  and
CXCR4 /  chimeras at day 6 after NP-CGG immuniza-
tion revealed similar numbers of CXCR4 /  (IgMa) and
CXCR4 /  (IgMb) antibody-secreting cells in the spleen
but strikingly elevated numbers of CXCR4 /  (IgMb) an-
tibody-secreting cells in blood (Fig. 7 B). By contrast, in
the control chimeras there were very few wild-type IgMb
antibody-secreting cells in blood, their frequency being
similar to the frequency of wild-type IgMa-secreting cells
in the blood of both types of mixed chimera (Fig. 7 B). We
also examined a further set of mixed chimeric animals for
their IgG response 14 d after immunization, focussing on
IgG1, the predominant IgG isotype produced in response
to immunization with NP (45). This analysis revealed a
striking deficit of CXCR4 /  IgG1b antibody-secreting
cells in the bone marrow, whereas CXCR4 /  IgG1a cells
were readily detectable, despite there being similar num-
bers of both types of antibody-secreting cells within the
spleen (Fig. 7 C). The control chimeras confirmed that
IgG1b antibody-secreting cells were competent to localize
within the bone marrow (Fig. 7 C) and that the deficiency,
therefore, reflected an intrinsic requirement for CXCR4 in
the plasma cells or their precursors.
Discussion
The above findings establish that as B cells differentiate
into plasma cells, they undergo a coordinated change in
chemokine receptor expression and chemokine responsive-
ness. This includes decreased cell surface expression of the
receptors for the B and T zone chemokines CXCL13,
CCL19, and CCL21, and decreased chemotactic respon-
siveness to these chemokines. At the same time, the
cells upregulate their sensitivity to the CXCR4 ligand
CXCL12. CXCL12 is highly expressed in bone marrow,
splenic red pulp, and lymph node medullary cords and our
genetic studies have demonstrated that CXCR4 is required
for normal plasma cell positioning within the spleen and for
normal accumulation of plasma cells within the bone mar-
row. We suggest a model where decreased responsiveness
to CXCL13, CCL19, and CCL21 helps direct plasma cells
out of B and T zones, while the CXCR4/CXCL12 recep-
tor–ligand pair regulates splenic red pulp localization and
bone marrow lodgment.
The possibility that plasma cells would have altered
chemokine receptor expression compared with B cells was
suggested by the finding that plasmacytomas lacked
CXCR5 expression (23, 24). In a recent study published
while our work was being completed, Wehrli and cowork-
ers demonstrated that plasma cells downregulate CXCR5
mRNA and have reduced responsiveness to CXCL13,
CCL19, and CXCL12 (46). Consistent with these reports,
we found that plasma cells downregulate surface CXCR5
and CCL19 receptors (presumably CCR7) and lose re-
sponsiveness to CXCL13, CCL19, and CCL21. Also in
agreement with Wehrli et al., we observed that plasma cells
maintain CXCR4 expression. However, in contrast to
their report, we found that plasma cells exhibited a signifi-
cant chemotactic response to CXCL12. The basis for this
difference in our findings is unclear, although it may reflect
differences in the sources of plasma cells or technical differ-
ences in the chemotaxis assays.
Genetic experiments have established that B cell entry to
lymphoid follicles depends on CXCR5 and its ligand,
CXCL13, (47, 48) and entry of T cells and dendritic cells
to the T zone depends on expression of CCR7 and ligands,
CCL19 and CCL21 (49, 50). Therefore, downregulation
of CXCR5 and CCR7, and decreased responsiveness to B
and T zone chemokines, seems likely to be an important
part of the mechanism promoting plasma cell movement
out of the B and T cell areas in spleen and lymph node. Al-
Figure 7. Intrinsic CXCR4 requirement for plasma cell accumulation
in bone marrow. (A) Mixed bone marrow and fetal liver chimeras were
generated by mixing bone marrow for IgHa B6 mice with CXCR4 /  or
CXCR4 /  IgHb fetal liver cells and reconstituting irradiated 129 (IgHa)
recipients. (B and C) After 6 wk, chimeric mice were immunized with
NP-CGG in alum and IgMa and IgMb (B) or IgG1a and IgG1b (C) anti-
body-secreting cells were measured 6 or 14 d later in spleen, blood, or
bone marrow as indicated. Data from animals reconstituted with wild-
type IgHa bone marrow and CXCR4 /  IgHb fetal liver are shown in
white (IgHa) and gray (IgHb) bars; data from animals reconstituted with
wild-type IgHa bone marrow and CXCR4 /  IgHb fetal liver are shown
in striped (IgHa) and black (IgHb) bars. Numbers of antibody-secreting
cells per organ or per milliliter of blood in each animal were measured as
indicated. Total splenocyte numbers for each group of animals differed by
 30%. Bars represent mean and error bars indicate 95% confidence inter-
vals for groups of three mice.53 Hargreaves et al.
though we found CXCL12 is expressed in the splenic red
pulp and lymph node medullary cords, our observations in
mice reconstituted with CXCR4-deficient fetal liver cells
suggest that CXCR4 does not play a limiting role in plasma
cell movement out of follicles or T cell areas. Perhaps
plasma cell exclusion from T and B zones occurs as a result
of displacement by recirculating lymphocytes. Consistent
with this, one study reported that in T cell–deficient mice,
plasma cells tended to accumulate in the area correspond-
ing to the T zone (51). However, the involvement of other
cues in directing plasma cells out of T or B cell areas has
not been excluded.
In the spleen, plasma cells leave the white pulp cords by
marginal zone bridging channels, areas where the T zone
interfaces with the red pulp (1). Plasma cells appear in these
regions as large foci before later moving deeper into the red
pulp where they become associated with vessels or connec-
tive tissue fibers (1). CXCL12 expression was detected in
most areas of the splenic red pulp, including the bridging
channels and in regions proximal to vessels and fibers (Fig.
1, and data not shown). We did not observe CXCL12 tran-
scripts in follicular mantle zones, although CXCL12-
expressing cells were sometimes observed in close proximity
with germinal centers. In a study of human tonsils, it was
reported that CXCL12 message could be detected in con-
nective tissue cells surrounding germinal centers, including
expression in follicular mantle zone areas (52). The basis for
the discrepancy between our findings and those of Bleul et
al. (52) is unclear but might reflect differences in chemo-
kine expression between specific pathogen-free mouse tis-
sue and inflammed human tonsil. In agreement with the
mouse CXCL12 expression data, CXCR4-deficient B cells
are able to form primary follicles that appear normal in
structure (Fig. 5, and reference 20). It remains to be deter-
mined whether CXCR4 and CXCL12 have a function in
the germinal center response. A role at some step preceding
the plasma cell is suggested by the lower number of IgG-
secreting cells generated in CXCR4 /  chimeras during the
primary response. Interestingly, the numbers of IgD  ma-
ture B cells in the red pulp of spleens from CXCR4 /  fe-
tal liver chimeras was substantially reduced (Fig. 5), sug-
gesting that lodgment of mature B cells in this area occurs
at least in part in response to CXCL12. Whether CXCL12
is involved in promoting lodgment of other cell types in
the splenic red pulp, such as activated CD8 T cells (53) and
NK cells (54), requires further investigation.
In the absence of CXCR4, plasma cells tended to re-
main in bridging channels and were often observed in or
adjacent to the splenic marginal zone (Fig. 5). The factors
guiding cells to the marginal zone are unknown. In con-
trast to effects in the red pulp, CXCR4-deficient B cells
were still efficient in populating the splenic marginal zone
(Fig. 5 B, and data not shown). As previous findings have
shown that B cell localization in the marginal zone is inde-
pendent of CXCR5/CXCL13 (28), but is sensitive to Per-
tussis toxin (55), a chemoattractant other than CXCL12 or
CXCL13 is likely to be involved. Although CXCR4 is
necessary for the normal distribution of plasma cells near
vessels and fibers in the splenic red pulp, expression of
CXCL12 is not limited to these locations (Fig. 1). There-
fore, we speculate that additional factors, such as extra-
cellular matrix proteins, adhesion molecules, or other
chemokines, act together with CXCR4 and CXCL12 to
regulate splenic plasma cell positioning.
In contrast to the disturbed plasma cell distribution
within spleen, we have so far not observed effects of
CXCR4 deficiency on plasma cell distribution or numbers
in lymph nodes (data not shown). However, a possible role
in microlocalization of cells within the medullary cords is
not excluded. In this context, it is interesting that Wehrli
and coworkers (46) focused on lymph node plasma cells
and found that the cells did not migrate to CXCL12. Fur-
ther work is needed to define whether CXCR4 and
CXCL12 function in regulating the distribution or proper-
ties of plasma cells within lymph nodes.
The bone marrow is an important site of plasma cell ac-
cumulation in humans and rodents (6). Recent studies have
indicated that bone marrow plasma cells may survive for
extended periods, possibly many months, and it has been
suggested that such long-lived cells make an important
contribution to the maintenance of serum antibody levels
long after antigen exposure (7, 15, 16). CXCR4 and
CXCL12 have well-established roles within the bone mar-
row. Bone marrow stromal cells were identified as one of
the most plentiful sources of CXCL12 (18, 35, 39, 40), and
more recently bone marrow sinusoidal endothelial cells
were found to express CXCL12 (56, 57) and to support
CXCL12-dependent rolling and tethering of CXCR4 
cells (57). CXCR4 and CXCL12 play important roles in
retaining pre-B cells and granulocytes in the bone marrow
(20, 21, 25). The ability of this chemokine receptor–ligand
pair to direct peripheral cell types to the bone marrow was
suggested by the finding that transgenic overexpression of
CXCR4 on CD4 T cells caused the cells to accumulate in
the bone marrow (58). Our findings indicate that CXCR4
is needed for efficient plasma cell accumulation in the bone
marrow. Presently, our studies do not distinguish between
a role in promoting entry to this compartment or in pro-
moting retention of cells after they have entered. They also
do not exclude the possibility that CXCL12 functions to
augment plasma cell survival within the marrow, although
the elevated numbers of CXCR4-deficient antibody-secret-
ing cells in circulation argues against CXCR4 function-
ing solely to transmit survival signals. We presently favor a
model where the function of CXCR4 and CXCL12 in
plasma cells is similar to its role in pre-B cells, promoting
retention within the bone marrow. In support of a similar
mechanism of action on these two cell populations, in in
vitro chemotaxis assays, plasma cells (Fig. 2), and pre-B
cells (19, 59, 60), both have elevated dose sensitivity to
CXCL12 compared with mature B cells.
In addition to CXCL12, several adhesion molecules
have been implicated in plasma cell localization within the
bone marrow. Mice lacking CD22 have reduced numbers
of bone marrow plasma cells (61) and recent conditional
gene ablation experiments (62, 63) have added to earlier54 CXCR4 Regulates Plasma Cell Distribution
evidence (64) implicating vascular cell adhesion molecule 1
and  4 integrins in B cell homing to bone marrow. Plasma
cells have high levels of  4 1 integrin expression (46, 65).
As CXCL12 has been shown to activate  4 integrin bind-
ing (66, 67), it seems likely that these molecules function
together in promoting plasma cell accumulation within the
bone marrow. Further investigation is required to deter-
mine the basis for the propensity of some plasma cells to re-
main in secondary lymphoid organs versus the propensity
of others, particularly those generated early during the sec-
ondary response, to home to the bone marrow. Our studies
suggest CXCR4 functions in both populations and there-
fore, we propose that other differences, perhaps responsive-
ness to other chemokines or differences in adhesion mole-
cule expression, account for the differing tropisms.
In summary, we have demonstrated that CXCR4 is nec-
essary for normal plasma cell accumulation in subcompart-
ments of splenic red pulp and within bone marrow. As well
as their implications for understanding normal antibody re-
sponses, our findings add to other studies implicating
CXCR4 and CXCL12 in directing leukemia cells to bone
marrow (40, 68), and they suggest that in cases where
CXCL12 is expressed at sites of chronic inflammation, such
as within the joint synovium of rheumatoid arthritis pa-
tients (69), it will contribute to the local retention of
plasma cells. This work also highlights the need to consider
the impact of CXCR4-blocking treatments, such as those
being investigated for anti-HIV therapy, on plasma cell
homing, and antibody responses.
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